|
May 1
|
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
|
|
Jan 9
|
What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
|
|
Dec 30
|
Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
|
|
Dec 21
|
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
|
|
May 23
|
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
|
|
May 20
|
Companies Like Galecto (NASDAQ:GLTO) Could Be Quite Risky
|
|
May 17
|
Galecto to Present Poster at Upcoming ATS 2023 International Conference
|